MapLight Therapeutics (MPLT) Share-based Compensation (2024 - 2025)
MapLight Therapeutics recorded quarterly Share-based Compensation of $35.5 million in Q4 2025, up 28316.8% quarter-over-quarter from $125000.0 in Q3 2025, and up 16498.6% year-over-year from N/an in Q4 2024.
MapLight Therapeutics' Share-based Compensation history runs 2 years deep, the most recent figure standing at $35.5 million for Q4 2025.
- In Q4 2025, Share-based Compensation rose 16498.6% year-over-year to $35.5 million; the TTM figure through Dec 2025 stood at $36.2 million (changed N/A YoY), while the FY2025 annual figure was $36.0 million, up 3233.89% from the prior year.
- Share-based Compensation came in at $35.5 million for Q4 2025 at MapLight Therapeutics, up from $125000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $35.5 million in Q4 2025 to a low of $125000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.15 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | 35.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 35.52 Mn |
| Dec 31, 2025 | 35.52 Mn |
| Sep 30, 2025 | 125,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Dec 31, 2024 | 214,000.00 |
| Dec 31, 2024 | 214,000.00 |
| Sep 30, 2024 | 354,000.00 |
| Sep 30, 2024 | 354,000.00 |